



# TEGO SCIENCE

## A World Leader in Cell Therapy & Advanced Regenerative Medicine

Tego Science is a Seoul-based biopharmaceutical company specializing in regenerative skin cell therapy for wound healing. Tego's chief strengths have been leading-edge technologies in cell culture, skin-graft manufacturing and cryopreservation. It is now evolving into wider regenerative medicine areas involving musculo-skeletal, ophthalmological and dermatological targets, with plans for overseas expansion. Tego Science has been listed in KOSDAQ since 2014.

### Main Products



CEO  
Saewha Jeon

Location  
93, Magokjungang 8-ro,  
Gangseo-Gu, Seoul 07794,  
Korea

Specialty  
1. Dermatological cell therapy,  
2. Musculo-skeletal cell  
therapy  
3. Ophthalmological cell therapy

Tel / Fax / E-mail  
T. 82-2-818-2900  
F. 82-2-2107-3173  
E. swbaek@tegoscience.com

Product(Ingredient/Formulation)	Use	Exporting Countries(E)	Remark
Holoderm® (Autologous Keratinocytes)	3rd degree burn		Launched
Kaloderm® (Allogenic Keratinocytes)	Deep 2rd degree burn, Diabetic Foot Ulcer	Mongolia, Indonesia	Launched
Rosmir® (Autologous Fibroblasts)	Wrinkles	Vietnam	Launched
Neoderm® (3D Human Skin)	Replacing animal testing	Japan	Launched

### R&D Pipeline

Project / Cell & Protein therapy	Indications	Discovery	Pre-Clinical	Clinical Trial			NDA
				I	II	III	
TPX-114 / Dermal fibroblasts (auto)	Full-thickness rotator-cuff tear	→					
TPX-115 / Dermal fibroblasts (allo)	Partial-thickness rotator-cuff tear	→					
TPX-113 / Keratinocytes (auto/allo)	Oral mucosal defects	→					
TPX-107 / Mucosal keratinocytes (auto)	Corneal defects	Investigator Initiated Trial					
TPX-109/ Chemokine	Cartilage defects	→					

\* Arrows indicate current progress with MFDS.